The approach to the endocrine patient is a clinical and decision-making process that integrates semiology, physiology and laboratory medicine to trace often nonspecific symptoms back to a measurable alteration in hormonal function, distinguishing functional, iatrogenic, paraneoplastic and endocrine organ diseases. In endocrinology, diagnosis rarely arises from a single finding: it requires every biochemical measurement to be placed within its context, which includes circadian and pulsatile rhythms, nutritional status and intercurrent illness, drugs and substances, renal and hepatic function, pregnancy, age and body composition. The strength of the discipline lies in the possibility of formulating testable hypotheses through reasoning based on axes and regulatory circuits, but its weakness is symmetrical: a test interpreted outside its context can generate overdiagnosis or therapeutic errors, with relevant clinical consequences.
A “maximum-level” endocrine consultation aims at three simultaneous objectives. The first is to rapidly recognize potentially time-dependent conditions, such as adrenal crisis, severe thyrotoxicosis, symptomatic hypercalcemia, recurrent hypoglycemia or compression from pituitary masses. The second is to establish an efficient diagnostic pathway, reducing unnecessary blood tests and imaging and selecting the right test at the right time. The third is to build a longitudinally sustainable management strategy, because many endocrine conditions require prolonged monitoring, titration and prevention of metabolic and cardiovascular complications. This page describes the general clinical principles; technical details on laboratory diagnostics, dynamic testing, biological variability, interferences and imaging are developed in the dedicated pages.
Endocrine reasoning starts from the recognition of recurrent pathophysiological patterns. A syndrome of hormone excess may result from autonomous hypersecretion, increased receptor sensitivity, reduced clearance or excess precursors converted peripherally; a deficiency syndrome may reflect loss of glandular parenchyma, deficient central trophic stimulation, receptor resistance or alterations in transport and metabolism. The difference is not academic: it changes which analytes should be measured, how they should be interpreted and which therapy should be chosen. In a classic hypothalamic pituitary peripheral axis, the coherence between the “tropic” hormone and the “peripheral” hormone makes it possible to distinguish primary from secondary or tertiary dysfunctions, but there are numerous exceptions: pulsatile secretion, binding systems, peripheral conversions and multiple feedback loops make integrated interpretation necessary, especially when values are borderline.
One operational principle is to distinguish “signal” from “noise”. A single hormonal finding must be evaluated against pre-test probability, clinical severity, consistency with other measurements, reproducibility and physiological plausibility. In the presence of nonspecific symptoms, the threshold for concluding “endocrine disease” must be high and guided by a coherent clinical picture; conversely, in the presence of signs with high predictive value, even modest biochemical alterations deserve further evaluation. The clinician must also recognize the role of iatrogenesis: glucocorticoids, opioids, antipsychotics, thyroid medications, oncological immunotherapies, antiandrogens and many other drug classes can mimic or mask endocrine diseases, alter hormone secretion or measurement, and modify the response to dynamic tests.
An axis-based approach provides a stable framework to avoid missing important diagnoses. Thyroid axis: disorders of TSH and thyroid hormones, goiter and nodules, autoimmunity and systemic consequences. Adrenocortical axis: adrenal insufficiency, hypercortisolism, hyperaldosteronism and pheochromocytoma with blood pressure and metabolic implications. Somatotropic and lactotropic axis: alterations in growth and body composition, galactorrhea and gonadal dysfunctions. Gonadotropic axis: infertility, male hypogonadism, menstrual dysfunctions and hyperandrogenism. Calcium phosphorus bone axis: hyperparathyroidism and hypoparathyroidism, osteoporosis and fragility. Glucose and lipid metabolism: diabetes, hypoglycemia, dyslipidemias and their endocrine connections. An excellent approach is one that can move between these categories without reducing the patient to a single axis, because comorbidities, drugs and systemic conditions often cause several circuits to interact simultaneously.
The endocrine history is a temporal reconstruction that relates symptoms, biological events and therapeutic interventions. The first operation is to transform an often fragmented narrative into a high-resolution timeline: when the symptoms began, how rapidly they progressed, which factors worsen or improve them, and which events preceded them, such as pregnancy, childbirth, infections, surgery, radiotherapy, major weight changes or treatment modifications. The temporal dimension is crucial because many endocrine conditions have typical kinetics: some are acute and dramatic, others slowly progressive; some show circadian or episodic fluctuations, others a monotonic course. A well-constructed timeline makes it possible to distinguish an endocrine disease from functional disorders or from the consequences of chronic systemic illness.
The second operation is to identify “cardinal” symptoms and separate them from common manifestations. In the thyroid field, heat or cold intolerance, tachycardia, tremor, changes in bowel transit, unexplained weight variation, skin and hair changes, sleep and mood disturbances matter, but objective signs and context are especially important. For the adrenocortical axis, hypercortisolism requires attention to skin fragility, bruising, proximal myopathy, fragility fractures and metabolic worsening; adrenal insufficiency requires attention to profound asthenia, hypotension, hyponatremia, weight loss and hyperpigmentation when primary. For the gonadal axis, fertility, libido, erection, menstrual regularity, vasomotor symptoms, galactorrhea and signs of androgenization are central. In the calcium bone axis, paresthesias and tetany point toward hypocalcemia, whereas nephrolithiasis, polyuria and bone pain may accompany hypercalcemia or hyperparathyroidism. In the metabolic area, patterns of hypoglycemia, weight changes, hunger, polydipsia and polyuria must be linked to objective measurements and the therapeutic context.
A third pillar is the pharmacological and “para-pharmacological” history, which is often the most common cause of apparently unexplained endocrine alterations. It is necessary to reconstruct doses, timing and routes of administration of glucocorticoids, including inhaled, topical and infiltrative formulations, because cumulative exposure can suppress the hypothalamic pituitary adrenal axis and mask clinical signs. Similarly, estrogens, testosterone therapy, antiandrogens, antithyroid drugs, amiodarone, lithium, antiepileptics, antiretrovirals, opioids and immunotherapies can alter secretion, transport or peripheral hormone conversion. Supplements and unregulated products may also contain iodine or thyroid analogues, androgens or sympathomimetic substances, and must be explored methodically. An accurate history also includes exposure to iodinated contrast agents, radiation therapy, endocrine surgery and procedures involving the pituitary gland or sellar region.
The family and genetic dimension is not accessory. A history of multiple endocrine tumors, hyperparathyroidism, pheochromocytoma, medullary thyroid carcinoma, pituitary tumors or cutaneous and neurological manifestations may suggest hereditary syndromes, which change the diagnostic strategy and the extent of screening in relatives. A family history of autoimmunity is also informative, because thyroiditis, autoimmune diabetes, adrenal insufficiency and celiac disease may coexist in autoimmune polyendocrine syndromes. In women, a complete reproductive history, pregnancy and the puerperium are essential for correctly interpreting prolactin, thyroid and adrenal function, and for identifying conditions such as postpartum thyroiditis, postpartum hypopituitarism or exacerbations of autoimmune diseases.
The endocrine physical examination is a search for signs that translate hormonal alterations into tissue changes. The assessment begins with vital signs and anthropometric measurements, because blood pressure, heart rate, weight, waist circumference and weight trajectory are often the first integrated “biomarker” of the endocrine metabolic profile. Blood pressure must be interpreted by considering posture, possible orthostatic hypotension and a history of paroxysmal hypertensive crises; heart rate and rhythm may point toward thyrotoxicosis or dysautonomia, but must always be contextualized with drugs and cardiopulmonary conditions.
General evaluation includes the skin, appendages and distribution of adipose tissue. Thin and fragile skin, bruising and wide violaceous striae, when associated with proximal myopathy, are more informative than simple weight gain in the suspicion of hypercortisolism. Dry skin, myxedema, bradycardia and psychomotor slowing suggest clinically significant hypothyroidism, whereas warm skin, sweating, tremor and hyperreflexia suggest hyperthyroidism, with the important caveat that anxiety, drugs and comorbidities can mimic part of the picture. Hyperpigmentation of skin folds and mucosae, when associated with hypotension and electrolyte disturbances, is a relevant sign of primary adrenal insufficiency. Acanthosis nigricans and signs of insulin resistance require metabolic assessment and, in selected settings, broader endocrine evaluation.
Examination of the neck includes thyroid palpation, assessment for goiter, nodules, tenderness, vascular bruits and compressive signs, as well as evaluation of lateral cervical and supraclavicular lymph nodes in appropriate contexts. Palpation must be integrated with observation during swallowing and, when necessary, with dedicated ultrasound; an apparently normal neck does not exclude thyroid disease, but a palpable nodule requires structured assessment. Eye examination may show signs of thyroid orbitopathy, which have therapeutic and prognostic implications. In the pituitary region, the physical examination does not “see” the sella, but attention to neurological signs, reported visual field defects and headache with compressive features is essential for determining the urgency and priority of imaging.
Examination of the reproductive system is an integral component: in men, evaluation of testicular volume, gynecomastia, hair distribution, signs of hypogonadism and testicular mass; in women, evaluation of signs of hyperandrogenism, acne, alopecia, hirsutism, galactorrhea and signs of hypoestrogenism. In both sexes, signs of bone fragility and reduced muscle mass should be assessed, because many endocrinopathies cause sarcopenia and increase the risk of falls and fractures. Targeted neurological evaluation, including proximal strength, reflexes and sensation, helps recognize endocrine myopathies, neuropathies associated with dysmetabolism and manifestations of hypocalcemia or hypercalcemia.
A non-negligible proportion of endocrine consultations includes conditions that require immediate action or an accelerated pathway. The first task is to recognize scenarios in which diagnostic delay increases morbidity and mortality. Adrenal crisis is a clinical emergency characterized by hemodynamic instability, dehydration, electrolyte disturbances and gastrointestinal symptoms, often precipitated by infections or stress in patients with known or undiagnosed adrenal insufficiency. In this setting, the priority is not to “complete” the outpatient workup, but to initiate acute management and, when possible, collect pre-treatment samples pragmatically when doing so does not delay treatment.
Severe thyrotoxicosis, including forms with cardiac complications, fever and altered mental status, requires rapid identification and co-management with emergency medicine. Similarly, symptomatic hypercalcemia, especially when associated with dehydration, neuropsychiatric changes or arrhythmias, requires timely assessment and treatment. Recurrent hypoglycemia, particularly in individuals not treated with glucose-lowering medications or in incongruous contexts, must be considered a potentially dangerous signal, requiring systematic documentation and etiological definition. Paroxysmal hypertensive crises with adrenergic symptoms, in selected clinical pictures, require a rapid pathway to exclude pheochromocytoma or paraganglioma, avoiding approaches that may be risky.
Other “red flags” are not emergencies in the strict sense but require prioritization: visual disturbances or progressive headache when a sellar mass is suspected; amenorrhea with neurological signs or significant galactorrhea; significant or unexplained hyponatremia or hyperkalemia; marked weight loss and asthenia with hypotension; resistant hypertension or hypokalemia suggesting hyperaldosteronism; fragility fractures at a young age; rapidly progressive hyperandrogenism or virilization; suspected endocrinopathies in pregnancy with severe symptoms. In these cases, the best approach is to immediately clarify the clinical objective, reduce the workup to a few high-yield steps and rapidly coordinate the necessary levels of care.
After history and physical examination, the endocrinologist must translate a suspicion into a measurement plan that maximizes information and minimizes bias. The first decision is whether the diagnosis can be initiated with basal tests or whether it requires a dynamic test from the outset. Many endocrine conditions can be identified with well-performed basal measurements, but quality often depends not on the laboratory but on the context: time of day, posture, fasting state, stress, menstrual cycle, pregnancy, acute illness, renal function and ongoing therapy. Excellent practice formalizes these variables in a repeatable way, because it makes results comparable over time and reduces the need for repeated testing.
A general principle is to separate two questions that are often confused. The first is “is there a reproducible biochemical alteration”. The second is “does this alteration explain the phenotype and require treatment”. In many situations, especially when values are close to reference limits, it is safer to confirm with repetition under controlled conditions before initiating an extensive cascade of tests or therapies. This is particularly true when the analyte is subject to pulsatile or circadian variation, or when known interferences exist. The aim is not to delay care, but to avoid decisions based on fragile data. In severe clinical pictures, by contrast, the logic is reversed: the priority is to secure the patient and reduce immediate risk, accepting that some diagnostic details will be completed in a second phase.
A high-level approach also includes the deliberate choice of the “minimum informative package” for each suspicion. For example, when thyroid dysfunction is suspected, the combination of TSH and FT4 is more informative than an indiscriminate panel; when adrenal insufficiency is suspected, morning sampling and attention to electrolytes and glucose provide rapid orientation; in gonadal disorders, timing in relation to the cycle and evaluation of nutritional status and stress are decisive; in calcium bone metabolism, correction for albumin and assessment of renal function are essential. The difference between “panel medicine” and “hypothesis-driven medicine” is often the difference between efficient diagnosis and diagnostic noise.
Modern endocrinology is strongly influenced by the phenomenon of incidentalomas, because imaging and laboratory testing are increasingly widespread. The correct approach is not to treat every finding as disease, but to evaluate two dimensions: functional risk and oncological or compressive risk, with a proportionate strategy. An incidental thyroid nodule, an adrenal mass discovered by chance or a pituitary microadenoma on MRI performed for headache are typical examples. In these contexts, the endocrinologist must distinguish between “anatomical presence” and “clinical significance”, preventing the patient from being defined by the finding. Communication is part of care: the way an incidentaloma is explained influences anxiety, adherence to follow-up and quality of life.
For incidental adrenal masses, evaluation has two fundamental objectives: excluding clinically relevant hormone secretion and characterizing the risk of malignancy or metastasis based on size and radiological features, taking into account the patient’s oncological context. The approach requires a structured pathway, because errors in sequence may lead to unnecessary interventions or missed recognition of important conditions. For incidental pituitary findings, in addition to hormonal evaluation, assessment of mass effect and the risk of optic chiasm compromise is central, with different priorities depending on size and symptoms. For thyroid nodules, the best assessment integrates history, physical examination, ultrasound and rational selection of fine-needle aspiration when indicated, avoiding indiscriminate screening that increases the diagnosis of clinically irrelevant microcarcinomas.
The cross-cutting concept is that an incidentaloma is not a diagnosis, but a starting point. Excellence consists in defining a risk-stratified plan, with reasonable follow-up and clear criteria for escalation, reducing repeated testing when the profile is stable. This approach protects the patient from the burden of medicalization and, at the same time, maintains high sensitivity for truly high-risk cases.
Many endocrine patients have cardiovascular, renal, hepatic or oncological comorbidities that modify clinical presentation and the safety of testing. In the frail, elderly or multimorbid patient, the question is not only “what is the diagnosis”, but “which intervention truly changes the outcome with an acceptable risk benefit profile”. For example, the intensity of thyroid or adrenal hormone replacement must consider heart disease, arrhythmic risk and functional reserve; the management of hyperaldosteronism or catecholamine excess must integrate antihypertensive therapy and cerebrovascular risk; the assessment of bone health must account for fall risk, sarcopenia and concomitant therapy with drugs that increase fragility.
Pregnancy represents a specific chapter, because it changes reference ranges, binding, volume of distribution and the physiology of multiple axes. A high-level approach requires that common symptoms of pregnancy are neither trivialized nor overinterpreted, but read carefully when signs of thyroid, adrenal or metabolic dysfunction emerge. The choice of tests and drugs must consider fetal safety, gestational timing and realistic objectives. The puerperium is also a high-risk period for autoimmune manifestations and decompensation in sensitive axes.
Critical therapies and acute illnesses represent a further scenario in which the endocrinologist must modulate diagnostic ambition and pragmatism. Under conditions of systemic stress, some hormones may vary adaptively, and some measurements may lose significance. The clinical priority is to define what is “immediately treatable” versus what requires reassessment later in a stable phase. The optimal approach includes scheduled reassessment plans, with written instructions and conditions for withdrawal or modification of therapies that may interfere with subsequent interpretation.
In endocrinology, diagnosis is often the beginning of a long pathway, and the quality of communication determines concrete outcomes. An effective therapeutic plan requires the patient to understand objectives, expected response times, warning signs and monitoring methods. This is particularly important in replacement therapies and in conditions in which the dose must be adjusted over time, because adherence, timing of intake and pharmacological interactions directly influence efficacy and safety. Excellent management always clarifies what to measure, when to measure it, under which conditions and according to which criteria change should be interpreted.
Shared decision-making is not a formality but a necessity, because many endocrine choices involve trade-offs between symptoms, long-term risk and therapeutic burden. In the treatment of subclinical dysfunctions, in the assessment of incidentalomas and in the prevention of metabolic complications, the patient’s informed preference is an integral part of the strategy. Well-designed follow-up includes the definition of clinical, biochemical and, when indicated, instrumental targets, with a realistic schedule and attention to reducing pre-analytical variability.
Finally, the endocrinologist must maintain a preventive perspective. Many endocrinopathies are associated with cardiovascular risk, bone fragility, sarcopenia, mood and sleep disturbances. Follow-up should include assessment of blood pressure, weight and body composition, fracture risk, physical activity and nutrition, smoking and alcohol, and targeted screening according to relevant guidelines. World-class quality is also measured by the ability to prevent complications and reduce the overall impact of disease on the patient’s life.